Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$18.55 - $39.96 $242,671 - $522,756
13,082 New
13,082 $502,000
Q1 2021

May 17, 2021

SELL
$13.08 - $49.6 $31,326 - $118,792
-2,395 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$36.36 - $52.71 $87,082 - $126,240
2,395 New
2,395 $110,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Fora Capital, LLC Portfolio

Follow Fora Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fora Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fora Capital, LLC with notifications on news.